Track topics on Twitter Track topics that are important to you
Man, Alzheimer’s. That’s my reaction to yesterday’s news in the field. Merck started things off with news of their last-ditch attempt to see if their beta-secretase (BACE) inhibitor verubecestat (MK-8931) could be useful. I’ve been writing about that one for a while – here’s 2012, when they announced that the compound would move into Phase
Original Article: More Rough Alzheimer’s NewsNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...